These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients. Garcia-Morales R; Carreno M; Mathew J; Cirocco R; Zucker K; Ciancio G; Burke G; Roth D; Temple D; Fuller L; Esquenazi V; Eskind L; Kenyon NS; Ricordi C; Tzakis A; Miller J Transplantation; 1998 Apr; 65(7):956-65. PubMed ID: 9565101 [TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory Effects of Different Cellular Therapies of Bone Marrow Origin on Chimerism Induction and Maintenance Across MHC Barriers in a Face Allotransplantation Model. Hivelin M; Klimczak A; Cwykiel J; Sonmez E; Nasir S; Gatherwright J; Siemionow M Arch Immunol Ther Exp (Warsz); 2016 Aug; 64(4):299-310. PubMed ID: 26708158 [TBL] [Abstract][Full Text] [Related]
4. Chimerism and tolerance: past, present and future strategies to prolong renal allograft survival. Tantisattamo E; Leventhal JR; Mathew JM; Gallon L Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):63-74. PubMed ID: 33186221 [TBL] [Abstract][Full Text] [Related]
5. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244 [TBL] [Abstract][Full Text] [Related]
6. Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipients. Hong T; Zhang M; Fan J Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD009698. PubMed ID: 26457607 [TBL] [Abstract][Full Text] [Related]
7. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207 [TBL] [Abstract][Full Text] [Related]
8. Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation. Scandling JD; Busque S; Shizuru JA; Lowsky R; Hoppe R; Dejbakhsh-Jones S; Jensen K; Shori A; Strober JA; Lavori P; Turnbull BB; Engleman EG; Strober S Am J Transplant; 2015 Mar; 15(3):695-704. PubMed ID: 25693475 [TBL] [Abstract][Full Text] [Related]
9. Current status of tolerance in kidney transplantation. Chandran S; Feng S Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):591-601. PubMed ID: 27636772 [TBL] [Abstract][Full Text] [Related]
10. A clinically feasible approach to induce delayed tolerance in recipients of prior kidney or vascularized composite allotransplants. Chen B; Xu H; Corbin DR; Ildstad ST Transplantation; 2012 Oct; 94(7):671-8. PubMed ID: 22948444 [TBL] [Abstract][Full Text] [Related]
11. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related]
12. Inducing Transient Mixed Chimerism for Allograft Survival Without Maintenance Immunosuppression With Combined Kidney and Bone Marrow Transplantation: Protocol Optimization. Lee KW; Park JB; Park H; Kwon Y; Lee JS; Kim KS; Chung YJ; Rhu JS; Choi S; Kwon GY; Kim HJ; Kang ES; Jung CW; Shin EC; Kawai T; Kim SJ; Joh JW Transplantation; 2020 Jul; 104(7):1472-1482. PubMed ID: 31634324 [TBL] [Abstract][Full Text] [Related]
13. A Prospective Controlled Trial to Evaluate Safety and Efficacy of Oberbauer R; Edinger M; Berlakovich G; Kalhs P; Worel N; Heinze G; Wolzt M; Lion T; Wekerle T Front Med (Lausanne); 2020; 7():634260. PubMed ID: 33585521 [No Abstract] [Full Text] [Related]
16. Efficacy and Safety of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Antibody-Mediated Rejection After Kidney Transplantation- A Single-Arm, Two-Dosing-Regimen, Phase I/II Study. Wei Y; Chen X; Zhang H; Su Q; Peng Y; Fu Q; Li J; Gao Y; Li X; Yang S; Ye Q; Huang H; Deng R; Li G; Xu B; Wu C; Wang J; Zhang X; Su X; Liu L; Xiang AP; Wang C Front Immunol; 2021; 12():662441. PubMed ID: 34248942 [TBL] [Abstract][Full Text] [Related]
17. Immune Tolerance Induction Using Cell-Based Strategies in Liver Transplantation: Clinical Perspectives. Wang P; Jiang Z; Wang C; Liu X; Li H; Xu D; Zhong L Front Immunol; 2020; 11():1723. PubMed ID: 33013824 [TBL] [Abstract][Full Text] [Related]
18. Current concepts and perspectives of immunosuppression in organ transplantation. Scherer MN; Banas B; Mantouvalou K; Schnitzbauer A; Obed A; Krämer BK; Schlitt HJ Langenbecks Arch Surg; 2007 Sep; 392(5):511-23. PubMed ID: 17450373 [TBL] [Abstract][Full Text] [Related]
19. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527 [TBL] [Abstract][Full Text] [Related]
20. Administration of Antithymocyte Globulin (Rabbit) to Treat a Severe, Mixed Rejection Episode in a Pregnant Renal Transplant Recipient. Kutzler HL; Ye X; Rochon C; Martin ST Pharmacotherapy; 2016 Apr; 36(4):e18-22. PubMed ID: 26892892 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]